| |
CD19/22
|
CD19/CD20
|
Axi-Cel
|
Tisa-Cel
|
Liso-Cel
|
|---|
| |
(Alexander)
| |
(Zuma-1)
|
(Juliet)
|
(Transcend)
|
|---|
|
Phase
|
1
|
1
|
2
|
2
|
2
|
|
Patients (n)
|
33
|
12
|
111
|
93
|
256
|
|
Target
|
CD19, CD22
|
CD19, CD20
|
CD19
|
CD19
|
CD19
|
|
Co-stim
|
OX40, 41BB
|
41BB
|
CD28
|
41BB
|
41BB
|
|
CR
|
52%
|
42%
|
52%
|
40%
|
53%
|
|
Median PFS (month)
|
NA
|
NA
|
5.9
|
3
|
6.8
|
|
Median OS (month)
|
NA
|
NA
|
NR
|
12
|
21.1
|
|
CRS, any grade
|
33%
|
42%
|
93%
|
58%
|
42%
|
|
≥ 3
|
NA
|
0
|
13%
|
22%
|
2%
|
|
Neurotoxicity any grade
|
9%
|
8%
|
64%
|
21%
|
30%
|
|
≥ 3
|
0
|
0
|
28%
|
13%
|
10%
|
|
References
|
[33]
|
[34]
|
[30]
|
[8]
|
[5]
|
| |
ASH 2020, #600
|
ASH 2020, #404
|
NEJM, 2017
|
NEJM, 2019
|
Lancet, 2020
|
